SUDA FY16 Update; Several Patents Granted Internationally, Strong IP Portfolio, Operation and Staff Expansion

SUDA LTD made steady progress with its pipeline of OroMist® oral sprays in FY2016. This included finalising the design of a pivotal PK trial and meeting with the FDA regarding the Company’s SUD-001 sumatriptan oral spray for the treatment of migraine. During the financial year, SUDA was granted several patents in the US, Canada and other territories, strengthening its IP portfolio.

The Company is advancing towards its business development goals to out-license its first-in-class oral sprays to pharmaceutical companies across the world. Discussions with prospective partners span its treatments for malaria, insomnia, migraine, nausea, and erectile dysfunction, as well as the application of SUDA’s OroMist® technology to new compounds.

The Company’s operations have expanded in 2016 with the addition of new staff. SUDA also took full control of its novel sublingual antimalarial ArTiMist™ with the acquisition of the 20% minority shareholding in its subsidiary company, Malaria Research Company Pty Ltd (MRC).

SUDA anticipates that FY2017 will be an exciting year for the Company with the prospect of securing several commercial deals and creating significant shareholder value.

ABOUT SUDA LTD

SUDA Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, WA. The Company is developing low-risk oral sprays using novel formulations of existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums) include ease of use, lower dosage, reduced side effects and faster response time.

SUDA’s product pipeline includes first-in-class oral sprays for insomnia, malaria, migraine, nausea and vomiting, erectile dysfunction and pre-procedural anxiety.